Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patricia LoRusso

Showing results (41-50 of 164) with videos related to

Pageof 17
Sort By:
Cancer Chemotherapy and Pharmacology|April 5, 2011
Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumorsPatricia LoRusso, Geoffrey I Shapiro, Herbert Hurwitz, et al.
Investigational New Drugs|February 29, 2012
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumorsChristina M Annunziata, Elise C Kohn, Patricia LoRusso, et al.
Journal of Clinical Pharmacology|July 30, 2013
Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib, a first-in-class MEK inhibitor, in patients with cancerDonna S Cox, Kyri Papadopoulos, Lei Fang, et al.
Investigational New Drugs|April 8, 2021
First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancerFilip Janku, Patricia LoRusso, Aaron S Mansfield, et al.
Investigational New Drugs|October 12, 2012
A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumorsGeoffrey I Shapiro, Stewart McCallum, Laurel M Adams, et al.
Oncotargets and Therapy|April 3, 2024
Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case SeriesNoboru Yamamoto, Anthony Tolcher, Navid Hafez, et al.
Clinical Breast Cancer|September 27, 2021
A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast CancerPatricia LoRusso, Erika Hamilton, Cynthia Ma, et al.
Investigational New Drugs|May 11, 2002
Lack of in vitro-in vivo correlation of a novel investigational anticancer agent, SH 30Srinivasu Poondru, Ralph E Parchment, Vivek Purohit, et al.
Heliyon|August 18, 2023
A pilot study of volumetric and density tumor analysis of ACC patients treated with vorinostat in a phase II clinical trialMolly Malarkey, Alex P Toscano, Mohammad Hadi Bagheri, et al.
Journal of Hematology & Oncology|March 12, 2016
First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumorsTianhong Li, Patricia LoRusso, Michael L Maitland, et al.
Pageof 17

Showing results (41-50 of 164) with videos related to

Sort By:
Pageof 17
Cancer Chemotherapy and Pharmacology|April 5, 2011
Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumorsPatricia LoRusso, Geoffrey I Shapiro, Herbert Hurwitz, et al.
Investigational New Drugs|February 29, 2012
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumorsChristina M Annunziata, Elise C Kohn, Patricia LoRusso, et al.
Journal of Clinical Pharmacology|July 30, 2013
Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib, a first-in-class MEK inhibitor, in patients with cancerDonna S Cox, Kyri Papadopoulos, Lei Fang, et al.
Investigational New Drugs|April 8, 2021
First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancerFilip Janku, Patricia LoRusso, Aaron S Mansfield, et al.
Investigational New Drugs|October 12, 2012
A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumorsGeoffrey I Shapiro, Stewart McCallum, Laurel M Adams, et al.
Oncotargets and Therapy|April 3, 2024
Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case SeriesNoboru Yamamoto, Anthony Tolcher, Navid Hafez, et al.
Clinical Breast Cancer|September 27, 2021
A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast CancerPatricia LoRusso, Erika Hamilton, Cynthia Ma, et al.
Investigational New Drugs|May 11, 2002
Lack of in vitro-in vivo correlation of a novel investigational anticancer agent, SH 30Srinivasu Poondru, Ralph E Parchment, Vivek Purohit, et al.
Heliyon|August 18, 2023
A pilot study of volumetric and density tumor analysis of ACC patients treated with vorinostat in a phase II clinical trialMolly Malarkey, Alex P Toscano, Mohammad Hadi Bagheri, et al.
Journal of Hematology & Oncology|March 12, 2016
First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumorsTianhong Li, Patricia LoRusso, Michael L Maitland, et al.
Pageof 17